Ebola's Unmet Crisis: A Biotech's Radical Plea to Sidestep Science's Pace

NEW YORK, NY – June 19, 2026 – In the rarefied world of drug development, data is currency, and peer review is the gold standard. A small biopharmaceutical company, 101 Therapeutics, just threw that playbook into the fire. Facing a deadly and rapidly spreading Bundibugyo Ebola outbreak in Central Africa for which no approved treatment exists, the firm took the unprecedented step of publicly releasing its clinical trial data for an experimental drug, 101-PGC-005, before it has been vetted by scientific journals. By posting a manuscript to the preprint server medRxiv, the company is making a high-stakes appeal directly to the court of global public opinion and, more importantly, to the regulators, clinicians, and health agencies on the front lines of the crisis. It’s a move that pits the urgent, life-or-death realities of an epidemic against the methodical, time-honored process of scientific validation, raising a critical question: in a public health emergency, how fast is fast enough?

A Calculated Gamble in a Public Health Vacuum

The crisis fueling this gambit is stark. As of this week, the World Health Organization (WHO) reports over 900 confirmed cases and more than 230 deaths from Bundibugyo virus disease in the Democratic Republic of Congo (DRC), with a case fatality rate hovering around 26%. The outbreak, declared a Public Health Emergency of International Concern in May, has already spilled into neighboring Uganda. Unlike the more infamous Zaire ebolavirus, for which vaccines and effective antibody treatments now exist, the Bundibugyo strain has no approved countermeasures. Patients receive only supportive care. This therapeutic void is a direct consequence of market dynamics; less common strains attract less R&D investment, leaving entire populations vulnerable when they inevitably emerge.

Into this vacuum steps 101 Therapeutics, a privately-held firm with operations in Israel and New Jersey. Its leadership is betting that the strength of its data will overcome the unconventional nature of its disclosure. “Peer review remains essential, and we are actively pursuing it,” said Dr. Michael Goldberg, the company's Founder and Chief Scientific Officer, in a press statement. “But an active Bundibugyo Ebola outbreak cannot wait for the usual publication timeline. Our goal is not to bypass scientific scrutiny, it’s to accelerate it.”

This strategy, while jarring, is not without precedent. The COVID-19 pandemic normalized the use of preprint servers to rapidly disseminate findings, a practice that many public health experts now argue is an ethical imperative during a crisis. The risk, however, is that un-vetted data can be flawed, misinterpreted, or create false hope. 101 Therapeutics is asking the world’s leading health authorities—from the WHO and Africa CDC to national regulators—to perform their own peer review on the fly, a monumental task in the heat of an outbreak response.

The Science of a 'Smarter' Steroid

The drug at the center of this storm, 101-PGC-005, is not an antiviral that attacks Ebola directly. Instead, it’s a host-directed therapy designed to quell the body’s own catastrophic overreaction to the virus. Many deaths from severe viral infections, including Ebola, are caused by a “cytokine storm,” a hyperinflammatory response where immune cells called macrophages release a flood of inflammatory signals that lead to vascular leakage, organ failure, and death. The company’s drug is a prodrug of dexamethasone, a powerful steroid, but with a critical twist.

It’s engineered to be a 'smarter' steroid. The molecule is designed for selective uptake by activated CD206-positive macrophages, the very cells driving the pathogenic inflammation. Once inside the macrophage, the drug becomes active, calming the cell's inflammatory output. Crucially, the company's data suggests the drug does this without leaking free dexamethasone into the bloodstream. This targeted mechanism aims to avoid the broad immunosuppression and debilitating side effects of conventional high-dose steroids—a key consideration when trying to fight a live virus where a functioning immune system is essential.

The evidence for this claim comes from a 309-patient Phase II/III trial in patients with severe COVID-19, another disease characterized by cytokine storm. According to the company's preprint manuscript, 101-PGC-005 was superior to standard dexamethasone, showed no treatment-related serious adverse events, and—critically—preserved the normal function of the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress-response system that systemic steroids typically shut down. It is this pathogen-agnostic, inflammation-taming profile that 101 Therapeutics believes makes it a compelling candidate for Bundibugyo.

From Preprint to Patient: The Regulatory Gauntlet

Releasing the data is only the first, and arguably easiest, step. The path from a preprint server to a patient in a Congolese Ebola treatment unit is a logistical and regulatory minefield. The company is seeking an emergency pathway, such as the WHO’s Monitored Emergency Use of Unregistered Interventions (MEURI) framework, which provides an ethical structure for using unproven therapies when no alternatives exist. National regulatory bodies in the DRC and Uganda would also have to grant authorization, a process that must balance unprecedented speed with due diligence.

Even with a green light, the logistical hurdles are immense. While the drug is a lyophilized (freeze-dried) small molecule, which is more stable than complex biologics, its administration via injection requires trained healthcare workers, sterile supplies, and a clinical infrastructure that is already stretched to its breaking point. Outbreak response in eastern DRC is complicated by armed conflict, community mistrust, and gaps in surveillance that mean the official case count is likely an underestimation. Any new intervention must be deployed with extreme cultural sensitivity and in close partnership with organizations like Doctors Without Borders (MSF), which have deep experience navigating these complex environments.

101 Therapeutics is now in the unenviable position of having a potential solution it cannot deploy on its own. Its public appeal is a search for partners—global health funders, larger pharmaceutical companies, and logistics experts—capable of navigating this gauntlet. The company has the science, but it needs the global health machinery to turn a promising molecule into a life-saving medicine.

A New Blueprint for Crisis Response?

Whether 101-PGC-005 is ever used against Bundibugyo Ebola remains uncertain. The data must be rigorously scrutinized, and the risks of deploying an experimental drug in a chaotic outbreak setting are profound. Yet the move by 101 Therapeutics illuminates a larger systemic issue: the failure of the traditional, market-driven pharmaceutical model to prepare for predictable threats from less-profitable pathogens. The company's strategy—leveraging data from a more common disease (COVID-19) to justify use in a neglected one (Bundibugyo Ebola)—may represent a new, if controversial, blueprint for bridging this gap.

For now, the world’s top virologists, regulators, and ethicists have been handed a complex problem with a ticking clock. They must weigh the promise of a novel therapeutic against the peril of unverified data, all while lives hang in the balance. The decision they make will not only impact the course of the current Ebola outbreak but could set a powerful precedent for how we respond to the inevitable epidemics of the future.